Influence of the Radiation Dose to Salivary Glands on Xerostomia in Patients with Head and Neck Carcinomas

Journals Menu

Follow SCIRP

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org

Citations h5-index & Ranking

"Influence of the Radiation Dose to Salivary Glands on Xerostomia in Patients with Head and Neck Carcinomas"
written by André Buchali, Christina Schröder, Dietrich Sidow, Eyck Blank,
published by Journal of Cancer Therapy, Vol.4 No.1, 2013

has been cited by the following article(s):

[1]	Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review
	Nuclear Medicine …, 2022

[2]	Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand
	Annals of Nuclear …, 2021

[3]	Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617
	2016

[4]	Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu] DKFZ-PSMA-617
	Molecular Imaging and Biology, 2016

[5]	How Safe Are Reduced Doses per Fraction in Target Volumes of 2 nd to 4 th Order in the Simultaneous Integrated Boost Irradiation Technique in Head and Neck Carcinoma Patients?
	Journal of Cancer Therapy, 2015

[6]	How Safe Are Reduced Doses per Fraction in Target Volumes of 2nd to 4th Order in the Simultaneous Integrated Boost Irradiation Technique in Head and Neck …
	2015

[7]	How Safe Are Reduced Doses per Fraction in Target Volumes of 2nd to 4th Order in the Simultaneous Integrated Boost Irradiation Technique in Head and …
	2015

[8]	O tratamento oncológico ea sua relação com a xerostomia
	2014

[9]	Manifestações orais em pacientes submetidos a radioterapia de cabeça e pescoço
	2013

[10]	Lesão cariosa é um defeito superficial generalizado

[1]	Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review Nuclear Medicine Communications, 2022 DOI:10.1097/MNM.0000000000001535

[2]	Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review Nuclear Medicine Communications, 2022 DOI:10.1097/MNM.0000000000001535

[3]	Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review Nuclear Medicine Communications, 2022 DOI:10.1097/MNM.0000000000001535

[4]	Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review Nuclear Medicine Communications, 2022 DOI:10.1097/MNM.0000000000001535

[5]	Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand Annals of Nuclear Medicine, 2021 DOI:10.1007/s12149-021-01659-8

[6]	Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617 Molecular Imaging and Biology, 2016 DOI:10.1007/s11307-016-0942-0

[7]	How Safe Are Reduced Doses per Fraction in Target Volumes of 2^nd to 4^th Order in the Simultaneous Integrated Boost Irradiation Technique in Head and Neck Carcinoma Patients? Journal of Cancer Therapy, 2015 DOI:10.4236/jct.2015.62023

Follow SCIRP